The role of positive information provision in open-label placebo effects.

expectation non-deceptive placebo open label placebo physical well-being placebo effects psychological well-being

Journal

Applied psychology. Health and well-being
ISSN: 1758-0854
Titre abrégé: Appl Psychol Health Well Being
Pays: England
ID NLM: 101502957

Informations de publication

Date de publication:
11 2023
Historique:
received: 07 12 2022
accepted: 06 03 2023
medline: 6 11 2023
pubmed: 19 3 2023
entrez: 18 3 2023
Statut: ppublish

Résumé

Open label placebos (OLPs) appear generally efficacious among clinical samples, but the empirical evidence regarding their use in non-clinical and sub-clinical samples, as well as when administered independent of a convincing rationale, is mixed. Healthy participants (N = 102) were randomised to either a 6-day course of OLP pills with information provision (OLP-plus: N = 35), without information provision (OLP-only: N = 35), or no-treatment control group (N = 32). OLP pills were described as enhancing physical (symptoms and sleep) and psychological (positive and negative emotional) well-being. Well-being was assessed at baseline and on Day 6. Expectancies and adherence were measured. OLP administration interacted with baseline well-being. The OLP-plus group demonstrated increased well-being on all outcomes other than positive emotions, but only when they reported decreased baseline well-being. OLP-only and control groups did not differ. The OLP-plus group demonstrated elevated expectancies, that mediated the OLP effect on physical symptoms relative to control, but only when well-being was lower than average at baseline (i.e. moderated-mediation). Results demonstrate the importance of information provided with OLPs. The moderating effect of baseline outcomes may reconcile inconsistent results regarding clinical and non-clinical samples. Accounting for baseline symptoms in non-clinical and sub-clinical samples is likely to enhance our understanding of when OLPs are effective.

Identifiants

pubmed: 36932997
doi: 10.1111/aphw.12444
doi:

Banques de données

ANZCTR
['ANZCTRN12617001092381']

Types de publication

Randomized Controlled Trial Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

1406-1426

Informations de copyright

© 2023 The Authors. Applied Psychology: Health and Well-Being published by John Wiley & Sons Ltd on behalf of International Association of Applied Psychology.

Références

Andrews, A., & Chong, J. L. Y. (2011). Exploring the wellbeing of students studying at an Australian university. Journal of the Australian and New Zealand Student Services Association, 37, 9-38. https://search.informit.org/doi/10.3316/ielapa.201109175
Psychology Foundation of Australia. (2018). Depression Anxiety Stress Scales (DASS). (accessed October 2022). http://www2.psy.unsw.edu.au/dass//
Ballou, S., Haas, J. W., Iturrino, J., Nee, J., Kirsch, I., Rangan, V., Cheng, V., Lembo, A., Kaptchuk, T. J., & Kelley, J. M. (2022). Psychological predictors of response to open-label versus double-blind placebo in a randomized controlled trial in irritable bowel syndrome. Psychosomatic Medicine, 84(6), 738-746. https://doi.org/10.1097/PSY.0000000000001078
Barnes, K., Yu, A., Josupeit, J., & Colagiuri, B. (2019). Deceptive but not open label placebos attenuate motion-induced nausea. Journal of Psychosomatic Research, 125, 109808. https://doi.org/10.1016/j.jpsychores.2019.109808
Blease, C. R., Bernstein, M. H., & Locher, C. (2020). Open-label placebo clinical trials: Is it the rationale, the interaction or the pill? BMJ Evidence-Based Medicine, 25(5), 159-165. https://doi.org/10.1136/bmjebm-2019-111209
Blease, C. R., Bishop, F. L., & Kaptchuk, T. J. (2017). Informed consent and clinical trials: Where is the placebo effect? BMJ, 356, j463. https://doi.org/10.1136/bmj.j463
Bräscher, A.-K., Ferti, I.-E., & Witthöft, M. (2022). Open-label placebo effects on psychological and physical well-being: A conceptual replication study. Clinical Psychology in Europe, 4, e7679. https://doi.org/10.32872/cpe.7679
Cardinal, R. N., & Aitken, M. R. F. (2006). ANOVA for the behavioural sciences researcher. Lawrence Erlbaum Associates Publishers.
Carvalho, C., Caetano, J. M., Cunha, L., Rebouta, P., Kaptchuk, T. J., & Kirsch, I. (2016). Open-label placebo treatment in chronic low back pain: A randomized controlled trial. Pain, 157(12), 2766-2772. https://doi.org/10.1097/j.pain.0000000000000700
Charlesworth, J. E. G., Petkovic, G., Kelley, J. M., Hunter, M., Onakpoya, I., Roberts, N., Miller, F. G., & Howick, J. (2017). Effects of placebos without deception compared with no treatment: A systematic review and meta-analysis. Journal of Evidence-Based Medicine, 10(2), 97-107. https://doi.org/10.1111/jebm.12251
Cohen, J., Cohen, P., West, S. G., & Aiken, L. S. (2003). Applied Multiple Regression/Correlation Analysis for the Behavioral Sciences. Lawrence Earlbaum Associates.
Colloca, L., & Howick, J. (2018). Placebos without deception: Outcomes, mechanisms, and ethics. International Review of Neurobiology, 138, 219-240. https://doi.org/10.1016/bs.irn.2018.01.005
Disley, N., Kola-Palmer, S., & Retzler, C. (2021). A comparison of open-label and deceptive placebo analgesia in a healthy sample. Journal of Psychosomatic Research, 140, 110298. https://doi.org/10.1016/j.jpsychores.2020.110298
El Brihi, J., Horne, R., & Faasse, K. (2019). Prescribing placebos: An experimental examination of the role of dose, expectancies, and adherence in open-label placebo effects. Annals of Behavioral Medicine, 53(1), 16-28. https://doi.org/10.1093/abm/kay011
Enck, P., Bingel, U., Schedlowski, M., & Rief, W. (2013). The placebo response in medicine: Minimize, maximize or personalize? Nature Reviews Drug Discovery, 12(3), 191-204. https://doi.org/10.1038/nrd3923
Eriksen, H. R., Ihlebaek, C., & Ursin, H. (1999). A scoring system for subjective health complaints (SHC). Scandinavian Journal of Public Health, 27(1), 63-72. https://doi.org/10.1177/14034948990270010401
Faasse, K., Perera, A., Loveys, K., Grey, A., & Petrie, K. J. (2017). Enhancing treatment effectiveness through social modelling: A pilot study. Psychology & Health, 32(5), 626-637. https://doi.org/10.1080/08870446.2017.1293056
Filipkowski, K. B., Smyth, J. M., Rutchick, A. M., Santuzzi, A. M., Adya, M., Petrie, K. J., & Kaptein, A. A. (2010). Do healthy people worry? Modern health worries, subjective health complaints, perceived health, and health care utilization. International Journal of Behavioral Medicine, 17(3), 182-188. https://doi.org/10.1007/s12529-009-9058-0
Flowers, K. M., Patton, M. E., Hruschak, V. J., Fields, K. G., Schwartz, E., Zeballos, J., Kang, J. D., Edwards, R. R., Kaptchuk, T. J., & Schreiber, K. L. (2021). Conditioned open-label placebo for opioid reduction after spine surgery: A randomized controlled trial. Pain, 162(6), 1828-1839. https://doi.org/10.1097/j.pain.0000000000002185
Friehs, T., Rief, W., Glombiewski, J. A., Haas, J., & Kube, T. (2022). Deceptive and non-deceptive placebos to reduce sadness: A five-armed experimental study. Journal of Affective Disorders Reports, 9, 100349. https://doi.org/10.1016/j.jadr.2022.100349
Geers, A. L., Faasse, K., Guevarra, D. A., Clemens, K. S., Helfer, S. G., & Colagiuri, B. (2021). Affect and emotions in placebo and nocebo effects: What do we know so far? Social and Personality Psychology Compass, 15(1), e12575. https://doi.org/10.1111/spc3.12575
Glombiewski, A. J., Rheker, J., Wittkowski, J., Rebstock, L., & Rief, W. (2019). Placebo mechanisms in depression: An experimental investigation of the impact of expectations on sadness in female participants. Journal of Affective Disorders, 256, 658-667. https://doi.org/10.1016/j.jad.2019.06.070
Goetz, C. G., Leurgans, S., Raman, R., & Stebbins, G. T. (2000). Objective changes in motor function during placebo treatment in PD. Neurology, 54(3), 710-714. https://doi.org/10.1212/wnl.54.3.710
Göhler, A. C., Haas, J. W., Sperl, M. F. J., Hermann, C., & Winkler, A. (2021). Placebo nasal spray protects female participants from experimentally induced sadness and concomitant changes in autonomic arousal. Journal of Affective Disorders, 295, 131-138. https://doi.org/10.1016/j.jad.2021.07.037
Guevarra, D. A., Moser, J. S., Wager, T. D., & Kross, E. (2020). Placebos without deception reduce self-report and neural measures of emotional distress. Nature Communications, 11(1), 3785. https://doi.org/10.1038/s41467-020-17654-y
Haas, J. W., Winkler, A., Rheker, J., Doering, B. K., & Rief, W. (2022). No open-label placebo effect in insomnia? Lessons learned from an experimental trial. Journal of Psychosomatic Research, 158, 110923. https://doi.org/10.1016/j.jpsychores.2022.110923
Hahn, A., Göhler, A. C., Hermann, C., & Winkler, A. (2022). Even when you know it is a placebo, you experience less sadness: First evidence from an experimental open-label placebo investigation. Journal of Affective Disorders, 304, 159-166. https://doi.org/10.1016/j.jad.2022.02.043
Henry, J. D., & Crawford, J. R. (2005). The short-form version of the Depression Anxiety Stress Scales (DASS-21): Construct validity and normative data in a large non-clinical sample. British Journal of Clinical Psychology, 44(2), 227-239. https://doi.org/10.1348/014466505X29657
Hoenemeyer, T. W., Kaptchuk, T. J., Mehta, T. S., & Fontaine, K. R. (2018). Open-label placebo treatment for cancer-related fatigue: A randomized-controlled clinical trial. Scientific Reports, 8(1), 2784. https://doi.org/10.1038/s41598-018-20993-y
Hruschak, V., Flowers, K. M., Patton, M., Merchantz, V., Schwartz, E., Edwards, R., Kaptchuk, T., Kang, J., Dossett, M., & Schreiber, K. (2022). Experiences of patients taking conditioned open-label placebos for reduction of postoperative pain and opioid exposure after spine surgery. International Journal of Behavioral Medicine. https://doi.org/10.1007/s12529-022-10114-5
Ikemoto, T., Ueno, T., Arai, Y.-C., Wakao, N., Hirasawa, A., Hayashi, K., & Deie, M. (2020). Open-label placebo trial among Japanese patients with chronic low back pain. Pain Research & Management, 2020, 6636979. https://doi.org/10.1155/2020/6636979
Kam-Hansen, S., Jakubowski, M., Kelley, J. M., Kirsch, I., Hoaglin, D. C., Kaptchuk, T. J., & Burstein, R. (2014). Altered placebo and drug labeling changes the outcome of episodic migraine attacks. Science Translational Medicine, 6(218), 218ra215. https://doi.org/10.1126/scitranslmed.3006175
Kaptchuk, T. J. (2018). Open-label placebo: Reflections on a research agenda. Perspectives in Biology and Medicine, 61(3), 311-334. https://doi.org/10.1353/pbm.2018.0045
Kaptchuk, T. J., Friedlander, E., Kelley, J. M., Sanchez, M. N., Kokkotou, E., Singer, J. P., Kowalczykowski, M., Miller, F. G., Kirsch, I., & Lembo, A. J. (2010). Placebos without deception: A randomized controlled trial in irritable bowel syndrome. PLoS ONE, 5(12), e15591. https://doi.org/10.1371/journal.pone.0015591
Kleine-Borgmann, J., Schmidt, K., Billinger, M., Forkmann, K., Wiech, K., & Bingel, U. (2021). Effects of open-label placebos on test performance and psychological well-being in healthy medical students: A randomized controlled trial. Scientific Reports, 11(1), 2130. https://doi.org/10.1038/s41598-021-81502-2
Kleine-Borgmann, J., Schmidt, K., Hellmann, A., & Bingel, U. (2019). Effects of open-label placebo on pain, functional disability, and spine mobility in patients with chronic back pain: A randomized controlled trial. Pain, 160(12), 2891-2897. https://doi.org/10.1097/j.pain.0000000000001683 https://journals.lww.com/pain/Fulltext/2019/12000/Effects_of_open_label_placebo_on_pain,_functional.22.aspx
Kreuter, M. W., & Wray, R. J. (2003). Tailored and targeted health communication: Strategies for enhancing information relevance. American Journal of Health Behavior, 27, S227-S232. https://doi.org/10.5993/AJHB.27.1.s3.6
Kube, T., Hofmann, V. E., Glombiewski, J. A., & Kirsch, I. (2021). Providing open-label placebos remotely-A randomized controlled trial in allergic rhinitis. PLoS ONE, 16(3), e0248367. https://doi.org/10.1371/journal.pone.0248367
Kube, T., Rief, W., Vivell, M.-B., Schäfer, N. L., Vermillion, T., Körfer, K., & Glombiewski, J. A. (2020). Deceptive and nondeceptive placebos to reduce pain: An experimental study in healthy individuals. The Clinical Journal of Pain, 36(2), 68-79. https://doi.org/10.1097/AJP.0000000000000781 https://journals.lww.com/clinicalpain/Fulltext/2020/02000/Deceptive_and_Nondeceptive_Placebos_to_Reduce.2.aspx
Leibowitz, K. A., Hardebeck, E. J., Goyer, J. P., & Crum, A. J. (2019). The role of patient beliefs in open-label placebo effects. Health Psychology, 38, 613-622. https://doi.org/10.1037/hea0000751
Lembo, A., Kelley, J. M., Nee, J., Ballou, S., Iturrino, J., Cheng, V., Rangan, V., Katon, J., Hirsch, W., Kirsch, I., Hall, K., Davis, R. B., & Kaptchuk, T. J. (2021). Open-label placebo vs double-blind placebo for irritable bowel syndrome: A randomized clinical trial. Pain, 162(9), 2428-2435. https://journals.lww.com/pain/Fulltext/2021/09000/Open_label_placebo_vs_double_blind_placebo_for.13.aspx, https://doi.org/10.1097/j.pain.0000000000002234
Leuchter, A. F., Cook, I. A., Witte, E. A., Morgan, M., & Abrams, M. (2002). Changes in brain function of depressed subjects during treatment with placebo. American Journal of Psychiatry, 159(1), 122-129. https://doi.org/10.1176/appi.ajp.159.1.122
Locher, C., Frey Nascimento, A., Kirsch, I., Kossowsky, J., Meyer, A., & Gaab, J. (2017). Is the rationale more important than deception? A randomized controlled trial of open-label placebo analgesia. Pain, 158(12), 2320-2328. https://journals.lww.com/pain/Fulltext/2017/12000/Is_the_rationale_more_important_than_deception__A.7.aspx, https://doi.org/10.1097/j.pain.0000000000001012
Mathur, A., Jarrett, P., Broadbent, E., & Petrie, K. J. (2018). Open-label placebos for wound healing: A randomized controlled trial. Annals of Behavioral Medicine, 52(10), 902-908. https://doi.org/10.1093/abm/kax057
Meeuwis, S. H., van Middendorp, H., van Laarhoven, A. I. M., Veldhuijzen, D. S., Lavrijsen, A. P. M., & Evers, A. W. M. (2019). Effects of open- and closed-label nocebo and placebo suggestions on itch and itch expectations. Frontiers in Psychiatry, 10, 436. https://doi.org/10.3389/fpsyt.2019.00436
Miller, F. G., & Colloca, L. (2009). The legitimacy of placebo treatments in clinical practice: Evidence and ethics. The American Journal of Bioethics, 9(12), 39-47. https://doi.org/10.1080/15265160903316263
Morales-Quezada, L., Mesia-Toledo, I., Estudillo-Guerra, A., O'Connor, K. C., Schneider, J. C., Sohn, D. J., Crandell, D. M., Kaptchuk, T., & Zafonte, R. (2020). Conditioning open-label placebo: A pilot pharmacobehavioral approach for opioid dose reduction and pain control. Pain Rep, 5(4), e828. https://doi.org/10.1097/pr9.0000000000000828
Morin, C. M., Belleville, G., Bélanger, L., & Ivers, H. (2011). The insomnia severity index: Psychometric indicators to detect insomnia cases and evaluate treatment response. Sleep, 34(5), 601-608. https://doi.org/10.1093/sleep/34.5.601
Muller, D., Judd, C. M., & Yzerbyt, V. Y. (2005). When moderation is mediated and mediation is moderated. Journal of Personality and Social Psychology, 89, 852- 863. https://doi.org/10.1037/0022-3514.89.6.852
Myers, J. L., & Well, A. D. (2003). Research design and statistical analysis (2nd ed.). Lawrence Erlbaum Associates Publishers.
Olliges, E., Stroppe, S., Haile, A., Reiß, F., Malhis, M., Funke, S. A., & Meissner, K. (2022). Open-label placebo administration decreases pain in elderly patients with symptomatic knee osteoarthritis-A randomized controlled trial. Frontiers in Psychiatry, 13, 853497. https://doi.org/10.3389/fpsyt.2022.853497
Pan, Y., Frank, M. L., Kaptchuk, T. J., & Nestoriuc, Y. (2022). “Let's see what happens:”-Women's experiences of open-label placebo treatment for menopausal hot flushes in a randomized controlled trial. PLoS ONE, 17(11), e0276499. https://doi.org/10.1371/journal.pone.0276499
Rathschlag, M., & Klatt, S. (2021). Open-label placebo interventions with drinking water and their influence on perceived physical and mental well-being. Frontiers in Psychology, 12, 658275. https://doi.org/10.3389/fpsyg.2021.658275
Rose, J. P., Geers, A. L., Rasinski, H. M., & Fowler, S. L. (2012). Choice and placebo expectation effects in the context of pain analgesia. Journal of Behavioral Medicine, 35(4), 462-470. https://doi.org/10.1007/s10865-011-9374-0
Sandler, A. D., & Bodfish, J. W. (2008). Open-label use of placebos in the treatment of ADHD: A pilot study. Child: Care, Health and Development, 34(1), 104-110. https://doi.org/10.1111/j.1365-2214.2007.00797.x
Sandler, A. D., Glesne, C. E., & Bodfish, J. W. (2010). Conditioned placebo dose reduction: A new treatment in attention-deficit hyperactivity disorder? Journal of Developmental & Behavioral Pediatrics, 31(5), 369-375. https://doi.org/10.1097/DBP.0b013e3181e121ed, https://journals.lww.com/jrnldbp/Fulltext/2010/06000/Conditioned_Placebo_Dose_Reduction__A_New.1.aspx
Schaefer, M., Denke, C., Harke, R., Olk, N., Erkovan, M., & Enge, S. (2019). Open-label placebos reduce test anxiety and improve self-management skills: A randomized-controlled trial. Scientific Reports, 9(1), 13317. https://doi.org/10.1038/s41598-019-49466-6
Schaefer, M., Harke, R., & Denke, C. (2016). Open-label placebos improve symptoms in allergic rhinitis: A randomized controlled trial. Psychotherapy and Psychosomatics, 85, 373-374. https://doi.org/10.1159/000447242
Schaefer, M., Hellmann-Regen, J., & Enge, S. (2021). Effects of open-label placebos on state anxiety and glucocorticoid stress responses. Brain Sciences, 11(4), 508. https://www.mdpi.com/2076-3425/11/4/508, https://doi.org/10.3390/brainsci11040508
Schaefer, M., Sahin, T., & Berstecher, B. (2018). Why do open-label placebos work? A randomized controlled trial of an open-label placebo induction with and without extended information about the placebo effect in allergic rhinitis. PLoS ONE, 13(3), e0192758. https://doi.org/10.1371/journal.pone.0192758
Schaefer, M., Kühnel, A., Schweitzer, F., Enge, S., & Gärtner, M. (2023). Neural underpinnings of open-label placebo effects in emotional distress. Neuropsychopharmacology, 48(3), 560-566. https://doi.org/10.1038/s41386-022-01501-3
Schienle, A., & Unger, I. (2021). Open-label placebo treatment to improve relaxation training effects in healthy psychology students: A randomized controlled trial. Scientific Reports, 11(1), 13073. https://doi.org/10.1038/s41598-021-92579-0
Schienle, A., Unger, I., & Schwab, D. (2022). Changes in neural processing and evaluation of negative facial expressions after administration of an open-label placebo. Scientific Reports, 12(1), 6577. https://doi.org/10.1038/s41598-022-10567-4
Schneider, T., Luethi, J., Mauermann, E., Bandschapp, O., & Ruppen, W. (2020). Pain response to open label placebo in induced acute pain in healthy adult males. Anesthesiology, 132(3), 571-580. https://doi.org/10.1097/aln.0000000000003076
Tennant, R., Hiller, L., Fishwick, R., Platt, S., Joseph, S., Weich, S., Parkinson, J., Secker, J., & Stewart-Brown, S. (2007). The Warwick-Edinburgh Mental Well-being Scale (WEMWBS): Development and UK validation. Health and Quality of Life Outcomes, 5(1), 63. https://doi.org/10.1186/1477-7525-5-63
von Wernsdorff, M., Loef, M., Tuschen-Caffier, B., & Schmidt, S. (2021). Effects of open-label placebos in clinical trials: A systematic review and meta-analysis. Scientific Reports, 11(1), 3855. https://doi.org/10.1038/s41598-021-83148-6
Yennurajalingam, S., Azhar, A., Lu, Z., Rodriguez, A. J., Arechiga, A. B., Guerra-Sanchez, M., Stanton, P., Andersen, C. R., Urbauer, D. L., & Bruera, E. (2022). Open-label placebo for the treatment of cancer-related fatigue in patients with advanced cancer: A randomized controlled trial. The Oncologist., 27, 1081-1089. https://doi.org/10.1093/oncolo/oyac184
Yzerbyt, V., Muller, D., Batailler, C., & Judd, C. M. (2018). New recommendations for testing indirect effects in mediational models: The need to report and test component paths. Journal of Personality and Social Psychology, 115(6), 929-943. https://doi.org/10.1037/pspa0000132
Zhou, E. S., Hall, K. T., Michaud, A. L., Blackmon, J. E., Partridge, A. H., & Recklitis, C. J. (2019). Open-label placebo reduces fatigue in cancer survivors: A randomized trial. Supportive Care in Cancer, 27(6), 2179-2187. https://doi.org/10.1007/s00520-018-4477-6

Auteurs

Kirsten Barnes (K)

School of Psychology, University of New South Wales, Sydney, New South Wales, Australia.

Emily Babbage (E)

School of Psychology, University of New South Wales, Sydney, New South Wales, Australia.

Jessica Barker (J)

School of Psychology, University of New South Wales, Sydney, New South Wales, Australia.

Natasha Jain (N)

School of Psychology, University of New South Wales, Sydney, New South Wales, Australia.

Kate Faasse (K)

School of Psychology, University of New South Wales, Sydney, New South Wales, Australia.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH